Dengue Fever
Conditions
Brief summary
The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?
Interventions
OTHERObservational studies did not involve any interventions
Sponsors
Foshan Hospital of Traditional Chinese Medicine
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria\*\*: * Meet the clinical diagnostic criteria for dengue fever, with blood indicators showing that the dengue antigen is positive. * No age limit for inclusion. * Voluntarily agree to participate in the study and sign the informed consent. * Complete clinical data available, including symptoms and laboratory tests, to support subsequent analysis. *
Exclusion criteria
\*\*: * Incomplete or unavailable clinical data. Patients will be excluded if sufficient laboratory data and symptoms cannot be collected. * Unable to understand or unwilling to sign the informed consent for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| WBC | From January 2024 to December 2024 | WBC (White Blood Cell count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as. |
| HGB (Hemoglobin) | From January 2024 to December 2024 | HGB (Hemoglobin), unit: g/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as. |
| PLT (Platelet count) | From January 2024 to December 2024 | PLT (Platelet count), unit: cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as. |
| ANC (Absolute Neutrophil Count) | From January 2024 to December 2024 | ANC (Absolute Neutrophil Count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as. |
Countries
China
Outcome results
None listed